Adam Trickey

ORCID: 0000-0003-3462-2898
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • HIV, Drug Use, Sexual Risk
  • Hepatitis C virus research
  • HIV/AIDS Research and Interventions
  • Hepatitis B Virus Studies
  • COVID-19 epidemiological studies
  • HIV-related health complications and treatments
  • Liver Disease Diagnosis and Treatment
  • HIV Research and Treatment
  • COVID-19 and Mental Health
  • HIV/AIDS drug development and treatment
  • Breast Implant and Reconstruction
  • Sex work and related issues
  • Data-Driven Disease Surveillance
  • Breast Cancer Treatment Studies
  • Reconstructive Surgery and Microvascular Techniques
  • COVID-19 Digital Contact Tracing
  • SARS-CoV-2 and COVID-19 Research
  • Opioid Use Disorder Treatment
  • Healthcare Policy and Management
  • Cardiac Imaging and Diagnostics
  • SARS-CoV-2 detection and testing
  • Viral Infections and Outbreaks Research
  • Acute Myocardial Infarction Research
  • Cardiovascular Function and Risk Factors
  • Systemic Sclerosis and Related Diseases

University of Bristol
2016-2025

National Institute for Health Research
2017-2023

University Hospitals Bristol NHS Foundation Trust
2015-2022

NIHR Bristol Biomedical Research Centre
2019-2022

At Bristol
2018-2020

Institute for Health Metrics and Evaluation
2016

University of Washington
2016

Bristol Royal Infirmary
2015

Derbyshire County Council
1974

BackgroundHealth care for people living with HIV has improved substantially in the past two decades. Robust estimates of how these improvements have affected prognosis and life expectancy are utmost importance to patients, clinicians, health-care planners. We examined changes 3 year survival patients starting combination antiretroviral therapy (ART) between 1996 2013.MethodsWe analysed data from 18 European North American HIV-1 cohorts. Patients (aged ≥16 years) were eligible this analysis...

10.1016/s2352-3018(17)30066-8 article EN cc-by The Lancet HIV 2017-05-11
Haidong Wang Tim M Wolock Austin Carter Grant Nguyen Hmwe Hmwe Kyu and 95 more Emmanuela Gakidou Simon I Hay Edward J Mills Adam Trickey William Msemburi Matthew M Coates Meghan Mooney Maya Fraser Amber Sligar Joshua A. Salomon Heidi J. Larson Joseph Friedman Amanuel Alemu Abajobir Kalkidan Hassen Abate Kaja Abbas Mohamed Magdy Abd El Razek Foad Abd-Allah Abdishakur Abdulle Semaw Ferede Abera Ibrahim Abubakar Laith J. Abu‐Raddad Niveen M E Abu-Rmeileh Gebre Yitayih Abyu Akindele Olupelumi Adebiyi Isaac Akinkunmi Adedeji Ademola Adelekan Adofo Koranteng Arsène Kouablan Adou Oluremi N Ajala Tomi Akinyemiju Nadia Akseer Faris Lami Ziyad Al‐Aly Khurshid Alam Noore Alam Deena Alasfoor Saleh Fahed Aldhahri Robert W Aldridge Miguel Angel Alegretti Alicia V Aleman Zewdie Aderaw Alemu Rafael Alfonso‐Cristancho Raghib Ali Ala’a Alkerwi François Alla Rajaa Mohammad Rajaa Al‐Raddadi Ubai Alsharif Elena Álvarez Nelson Alvis‐Guzmán Azmeraw T. Amare Alemayehu Amberbir A. Kofi Amegah Walid Ammar Stephen M. Amrock Carl Abelardo T. Antonio Palwasha Anwari Johan Ärnlöv Al Artaman Hamid Asayesh Rana Jawad Asghar Reza Assadi Suleman Atique Lydia S Atkins Euripide Frinel G Arthur Avokpaho Ashish Awasthi Beatriz Paulina Ayala Quintanilla Umar Bacha Alaa Badawi Aleksandra Barać Till Bärnighausen Arindam Basu Tigist Assefa Bayou Yibeltal Tebekaw Bayou Shahrzad Bazargan‐Hejazi Justin Beardsley Neeraj Bedi Derrick Bennett Isabela M. Benseñor Balem Demtsu Betsu Tariku J. Beyene Eesh Bhatia Zulfiqar A Bhutta Sibhatu Biadgilign Boris Bikbov Sait Mentes Birlik Donal Bisanzio Michael Brainin Alexandra Bražinová Nicholas J K Breitborde Alexandria Brown Michael Burch Zahid A Butt Julio César Campuzano Rosario Cárdenas

Timely assessment of the burden HIV/AIDS is essential for policy setting and programme evaluation. In this report from Global Burden Disease Study 2015 (GBD 2015), we provide national estimates levels trends incidence, prevalence, coverage antiretroviral therapy (ART), mortality 195 countries territories 1980 to 2015.For without high-quality vital registration data, estimated prevalence incidence with data antenatal care clinics population-based seroprevalence surveys, assumptions by age sex...

10.1016/s2352-3018(16)30087-x article EN cc-by The Lancet HIV 2016-07-19

People who have recently injected drugs are a priority population in efforts to achieve hepatitis C virus (HCV) elimination. This study estimated the prevalence and number of people with recent injecting drug use living HCV, proportion among all HCV infection at global, regional country-levels.Data from global systematic review antibody (previous year) were used estimate HCV. These data combined HCV.There an 6.1 million [95% uncertainty interval (UI) = 3.4-9.2] aged 15-64 years globally...

10.1111/add.14393 article EN Addiction 2018-07-23

<h2>Summary</h2><h3>Background</h3> The life expectancy of people with HIV taking antiretroviral therapy (ART) has increased substantially over the past 25 years. Most previous studies were based on data from first few years after starting ART, when mortality is highest. However, many have been successfully treated ART for years, and up-to-date prognosis are needed. We aimed to estimate in adults at least 1 year Europe North America 2015 onwards. <h3>Methods</h3> used Antiretroviral Therapy...

10.1016/s2352-3018(23)00028-0 article EN cc-by The Lancet HIV 2023-03-21

Mortality rates among people with HIV have fallen since 1996 following the widespread availability of effective antiretroviral therapy (ART). Patterns cause-specific mortality are evolving as population ages. We aimed to investigate longitudinal trends in starting ART Europe and North America.

10.1016/s2352-3018(23)00272-2 article EN cc-by The Lancet HIV 2024-01-24

BackgroundPrevious trials suggest lower long-term risk of mortality after invasive rather than non-invasive management patients with non-ST elevation myocardial infarction (NSTEMI), but the excluded very elderly patients. We aimed to estimate effect versus within 3 days peak troponin concentration on survival aged 80 years or older NSTEMI.MethodsRoutine clinical data for this study were obtained from five collaborating hospitals hosting NIHR Biomedical Research Centres in UK (all tertiary...

10.1016/s0140-6736(20)30930-2 article EN cc-by The Lancet 2020-08-01

Abstract Controlling COVID-19 transmission in universities poses challenges due to the complex social networks and potential for asymptomatic spread. We developed a stochastic model based on realistic mixing patterns evaluated alternative mitigation strategies. predict, plausible parameters, that if cases are half as infectious symptomatic cases, then 15% (98% Prediction Interval: 6–35%) of students could be infected during first term without additional control measures. First year main...

10.1038/s41467-021-25169-3 article EN cc-by Nature Communications 2021-08-17

Abstract Climate change is increasing the likelihood of drought in sub-Saharan Africa, where HIV prevalence high. Drought could increase transmission through various mediating mechanisms; we investigated these associations. We used data on people aged 15–59 from Population-Based Impact Assessment surveys 2016 Eswatini, Lesotho, Tanzania, Uganda, and Zambia. Survey were geospatially linked to precipitation for 2014–2016, with local droughts defined as cumulative rainfall between 2014 being...

10.1007/s10461-024-04280-8 article EN cc-by AIDS and Behavior 2024-02-20

Alcohol use is measured in diverse ways across settings. Harmonization of measures necessary to assess effects alcohol multi-cohort collaborations, such as studies people with HIV (PWH). Data were combined from 14 cohort (nine European, five North American) participating the Antiretroviral Therapy Cohort Collaboration. We analyzed data on adult PWH at any time 6 months before starting antiretroviral therapy. Five cohorts AUDIT-C and others used cohort-specific measures. harmonized grams/day,...

10.1111/acer.15522 article EN cc-by Alcohol Clinical and Experimental Research 2025-01-08

We investigated whether CD4:CD8 ratio and CD8 count were prognostic for all-cause, AIDS, non-AIDS mortality in virologically suppressed patients with high CD4 count.We used data from 13 European North American cohorts of human immunodeficiency virus-infected, antiretroviral therapy (ART)-naive adults who started ART during 1996-2010, followed the date they had ≥350 cells/μL (baseline). stratified Cox models to estimate unadjusted adjusted (for sex, people inject drugs, initiation year,...

10.1093/cid/cix466 article EN cc-by Clinical Infectious Diseases 2017-05-22

The World Health Organization (WHO) has developed a global health strategy to eliminate viral hepatitis. We project the treatment and prevention requirements achieve WHO HCV elimination target of reducing incidence by 80% HCV-related mortality 65% 2030 in Pakistan, which second largest burden worldwide.We an transmission model for calibrated it epidemiological data from national survey (2007), surveys among people who inject drugs (PWID), blood donor data. Current coverage came expert...

10.1093/ije/dyx270 article EN cc-by-nc International Journal of Epidemiology 2017-12-13

Background. CD4 count at start of combination antiretroviral therapy (ART) is strongly associated with short-term survival, but its association longer-term survival less well characterized. Methods. We estimated mortality rates (MRs) by time since ART (<0.5, 0.5–0.9, 1–2.9, 3–4.9, 5–9.9, and ≥10 years) among patients from 18 European North American cohorts who started during 1996–2001. Piecewise exponential models stratified cohort were used to estimate crude adjusted (for sex, age,...

10.1093/cid/ciw183 article EN cc-by Clinical Infectious Diseases 2016-03-29

Immediate breast reconstruction (IBR) is routinely offered to improve quality-of-life for women requiring mastectomy, but there are concerns that more complex surgery may delay adjuvant oncological treatments and compromise long-term outcomes. High-quality evidence lacking. The iBRA-2 study aimed investigate the impact of IBR on time therapy. Consecutive undergoing mastectomy ± cancer July–December, 2016 were included. Patient demographics, operative, complication data collected. Time from...

10.1038/s41416-019-0438-1 article EN cc-by British Journal of Cancer 2019-03-28

Background There is limited evidence on the use of high-sensitivity C-reactive protein (hsCRP) as a biomarker for selecting patients advanced cardiovascular (CV) therapies in modern era. The prognostic value mildly elevated hsCRP beyond troponin large real-world cohort unselected presenting with suspected acute coronary syndrome (ACS) unknown. We evaluated whether (up to 15 mg/L) was associated mortality risk, level, ACS. Methods and findings conducted retrospective study based National...

10.1371/journal.pmed.1003911 article EN cc-by PLoS Medicine 2022-02-22
Coming Soon ...